Applied Biosystems Announces New Genomic Analysis Platform
1,705 Views
Carlsbad, CA (OBBeC) - Applied Biosystems, a division of Life Technologies, has announced that it will begin shipment of a new, genomic analysis platform, the SOLiD 3 System, February 14.
According to the company, the new system delivers a roadmap that will ultimately enable scientists to sequence a human genome for less than $10,000 dollars in 2009.
This new genomics system enables life science researchers to sequence entire genomes of all organisms at a much lower cost, outlines the company. Additionally, it expands the menu of applications into gene expression and epigenetic analysis, ultimately allowing customers to move one step closer to mainstream use of genomic data for clinical research and personalized medicine.
As stated by Applied Biosystems, the SOLiD 3 System has generated 40 gigabases of data per sequencing run in its research and development laboratories, with an accuracy of 99.94% due to 2-base encoding algorithms. Moreover, the SOLiD System is also achieving 100 base pair read lengths per sequencing run, enabling the platform’s use for metagenomic and de novo applications. Additionally, the system has demonstrated up to 1 billion sequencing tags per run for RNA analysis applications.
“The launch of the SOLiD 3 System represents a revolutionary step in next-generation sequencing,” said Greg Lucier, Chairman and Chief Executive Officer of Life Technologies. “The ability to sequence an entire genome at ever lower costs and with greater efficiency will enable fundamental changes in how we identify and treat disease. Life Technologies is committed to remaining on the forefront of sequencing technology with the current generation, as well as future breakthroughs.”
The new SOLiD 3 System is utilizing the combined power of Life Technologies to enable a suite of integrated, application-focused workflow solutions. These workflows accelerate genomic discovery, characterization, and screening for large-scale genome mapping and disease studies.
Expanded Menu of Applications Encourages New Experimental Approaches
In order to understand complex biological processes, researchers need a comprehensive suite of applications to conduct global analysis of cellular networks at all levels. The SOLiD 3 System will dramatically improve research performance, throughput, quality, and cost across a wide range of applications, including epigenomic, transcriptome and genome analysis, driving standardization on a single platform. With the SOLiD 3 System, life science researchers will be able to conduct comprehensive investigations of gene variation, gene expression and gene regulation in tandem, in order to develop a more comprehensive, system-wide view of basic biological function.
By combining these applications with the availability of lower cost genomic data on the SOLiD 3 System, life scientists will be able to accelerate disease association and biomarker discovery studies to improve diagnostics and more effectively manage disease.
For more information, visit: www.appliedbiosystems.com and www.invitrogen.com
According to the company, the new system delivers a roadmap that will ultimately enable scientists to sequence a human genome for less than $10,000 dollars in 2009.
This new genomics system enables life science researchers to sequence entire genomes of all organisms at a much lower cost, outlines the company. Additionally, it expands the menu of applications into gene expression and epigenetic analysis, ultimately allowing customers to move one step closer to mainstream use of genomic data for clinical research and personalized medicine.
As stated by Applied Biosystems, the SOLiD 3 System has generated 40 gigabases of data per sequencing run in its research and development laboratories, with an accuracy of 99.94% due to 2-base encoding algorithms. Moreover, the SOLiD System is also achieving 100 base pair read lengths per sequencing run, enabling the platform’s use for metagenomic and de novo applications. Additionally, the system has demonstrated up to 1 billion sequencing tags per run for RNA analysis applications.
“The launch of the SOLiD 3 System represents a revolutionary step in next-generation sequencing,” said Greg Lucier, Chairman and Chief Executive Officer of Life Technologies. “The ability to sequence an entire genome at ever lower costs and with greater efficiency will enable fundamental changes in how we identify and treat disease. Life Technologies is committed to remaining on the forefront of sequencing technology with the current generation, as well as future breakthroughs.”
The new SOLiD 3 System is utilizing the combined power of Life Technologies to enable a suite of integrated, application-focused workflow solutions. These workflows accelerate genomic discovery, characterization, and screening for large-scale genome mapping and disease studies.
Expanded Menu of Applications Encourages New Experimental Approaches
In order to understand complex biological processes, researchers need a comprehensive suite of applications to conduct global analysis of cellular networks at all levels. The SOLiD 3 System will dramatically improve research performance, throughput, quality, and cost across a wide range of applications, including epigenomic, transcriptome and genome analysis, driving standardization on a single platform. With the SOLiD 3 System, life science researchers will be able to conduct comprehensive investigations of gene variation, gene expression and gene regulation in tandem, in order to develop a more comprehensive, system-wide view of basic biological function.
By combining these applications with the availability of lower cost genomic data on the SOLiD 3 System, life scientists will be able to accelerate disease association and biomarker discovery studies to improve diagnostics and more effectively manage disease.
For more information, visit: www.appliedbiosystems.com and www.invitrogen.com
Comments